Pain Therapeutics, Inc. (NASDAQ: PTIE) shares fell 53.3% to $1.27 after the company reported that it has received a complete response letter from the FDA. The FDA determined that REMOXY cannot be approved. Share volume was 11.6 million, soaring above an all-day average of only 233,000
